Morgan Stanley
TARS icon

Morgan Stanley’s Tarsus Pharmaceuticals TARS Stock Holding History

Morgan Stanley’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$136M Sell
1,944,272
-96,470
-5% -$6.74M 0.01% 1194
2025
Q4 		$167M Buy
2,040,742
+128,340
+7% +$9.58M 0.01% 1047
2025
Q3 		$114M Sell
1,912,402
-143,316
-7% -$7.06M 0.01% 1300
2025
Q2 		$83.3M Buy
2,055,718
+42,941
+2% +$1.93M 0.01% 1472
2025
Q1 		$103M Buy
2,012,777
+43,706
+2% +$2.16M 0.01% 1235
2024
Q4 		$109M Sell
1,969,071
-239,517
-11% -$10.9M 0.01% 1189
2024
Q3 		$72.6M Buy
2,208,588
+323,903
+17% +$9.1M 0.01% 1501
2024
Q2 		$51.2M Sell
1,884,685
-514,233
-21% -$17.3M ﹤0.01% 1735
2024
Q1 		$87.2M Sell
2,398,918
-1,516,458
-39% -$44.6M 0.01% 1294
2023
Q4 		$79.3M Buy
3,915,376
+3,841,557
+5,204% +$64.1M ﹤0.01% 1970
2023
Q3 		$1.31M Buy
73,819
+23,738
+47% +$420K ﹤0.01% 4641
2023
Q2 		$905K Buy
50,081
+17,886
+56% +$284K ﹤0.01% 4892
2023
Q1 		$405K Buy
32,195
+7,338
+30% +$107K ﹤0.01% 5373
2022
Q4 		$364K Buy
24,857
+587
+2% +$9.71K ﹤0.01% 5393
2022
Q3 		$416K Sell
24,270
-10,849
-31% -$172K ﹤0.01% 5350
2022
Q2 		$512K Buy
35,119
+23,908
+213% +$359K ﹤0.01% 5413
2022
Q1 		$188K Sell
11,211
-27
-0.2% -$501 ﹤0.01% 5959
2021
Q4 		$253K Sell
11,238
-17,292
-61% -$450K ﹤0.01% 5937
2021
Q3 		$615K Buy
28,530
+20,248
+244% +$501K ﹤0.01% 5359
2021
Q2 		$241K Buy
+8,282
New +$259K ﹤0.01% 5920
2021
Q1 		– Sell
-6,372
Closed -$263K – 7561
2020
Q4 		$263K Buy
+6,372
New +$182K ﹤0.01% 5445

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley's TARS Position: Q1 2026 in Review

Morgan Stanley reduced its Tarsus Pharmaceuticals (TARS) stake by 4.7% in Q1 2026, selling an estimated $6.74M and leaving 1,944,272 shares worth $136M. The position accounts for 0.01% of the portfolio, ranked #1194.

Morgan Stanley first reported a position in TARS in Q4 2020 and has held it in 21 quarters since. The position peaked at $167M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Morgan Stanley held 1,944,272 shares of Tarsus Pharmaceuticals worth $136M as of Q1 2026.
  • Morgan Stanley sold 96,470 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $6.74M.
  • Tarsus Pharmaceuticals made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1194 holding.
  • Morgan Stanley first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Morgan Stanley's Tarsus Pharmaceuticals position peaked at $167M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.